By Finance Pulse in IPO —

Maze Therapeutics Reports First Profit in 2024 IPO Filing

Maze Therapeutics, backed by Third Rock Ventures, reports its first profit for the first nine months of 2024 in its U.S. IPO filing. Explore Maze Therapeutics' financial growth.

A sleek, modern design featuring the Maze Therapeutics logo against a backdrop of financial charts a
Maze Therapeutics Reports First Profit in 2024 IPO Filing

Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its U.S. IPO filing.

Source